A part of Watch Media

MedWatchWednesday4 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchWednesday4 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Medtech

Coloplast bags DKK 9.2bn through rights issue

The sale of the 12.2 million new B shares took place at a price of DKK 755 per share. 
Photo: Coloplast / Pr
Photo: Coloplast / Pr
By marketwire & Christopher due karlsson

It did not take long from offering to completion of the private placement in Coloplast, which was announced on Tuesday evening and completed just after midnight on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Related articles:

  • With the acquisition of Icelandic Kerecis, Coloplast now expect a long-term organic growth of 8-10% from previously 7-9%. | Photo: Kerecis / Pr

    Coloplast acquires Kerecis and raises growth expectations

    For subscribers

  • Kerecis uses fish skin for a biological wound care product, and unlike human or mammalian tissue, the risk of transmitting infection to humans is gone, according to Coloplast, and the value chains are more attractive. | Photo: Kerecis / Pr

    Coloplast expects to grow Icelandic acquisition manifold in a few years

    For subscribers

  • Kerecis develops fish skin products for the treatment of chronic wounds, surgical wounds, burns and other wounds that have difficulty healing. | Photo: Kerecis / Pr

    Coloplast acquisition doubles in value in just one year

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Photo: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
  • FDA approves Novo Nordisk drug to treat rare condition


Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers



Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

For subscribers


Photo: Novo Nordisk / Pr
Pharma & biotech

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers


Foto: Stine Bidstrup
Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers


Foto: Tom Little
Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom

For subscribers


  • Foto: Tom Little

    FDA approves Novo Nordisk drug to treat rare condition

    The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

    For subscribers


  • Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

    Fujifilm expands management with former Leo executive

    The contract manufacturer has hired a chief people officer with immediate effect.

    For subscribers


  • Foto: Andrew Kelly/Reuters/Ritzau Scanpix

    Low share price may knock Galecto off the stock exchange

    Nasdaq has requested that the biotech company raise its share price to above USD 1.

    For subscribers


  • Foto: Mike Segar/Reuters/Ritzau Scanpix

    Snack maker keeps an eye on Novo Nordisk's obesity drug

    ”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

  • Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

    Olympus appoints new chief medical officer

    The new medical director is brought in from Medtronic. 

    For subscribers


  • Foto: Mike Blake

    Eli Lilly's head of diabetes and obesity retires

    Mike Mason announces that he will retire at the end of the year after 34 years with the company.

    For subscribers


Further reading

Foto: Kerecis / Pr
Medtech

Danske Bank: Acquisition of Icelandic wound care company will boost sales at Coloplast

However, the Danish bank sees less share price potential in the Coloplast stock than before.

For subscribers



Foto: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers



Novo Nordisk's manufacturing facility in Clayton, the US. | Foto: Novo Nordisk/pr
Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers


Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

For subscribers



Foto: Staff
Pharma & biotech

Novo Nordisk to sell Wegovy in the UK at a fraction of the US price

The price of weight loss drug Wegovy in the UK is completely different price than the in the US.

For subscribers



Foto: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

For subscribers


Jobs

  • Audit & Supplier Manager

  • VP of Software Development, Perfusion Tech

  • Senior Analytical Scientists

  • Senior Legal Councel

  • Senior QA Specialists (GMP or GCP)

  • Project Director, HR & ESG

  • Clinical Trial Manager

  • Scientist - Bioanalysis, Biologics

  • Clinical Supply Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Global Medical Manager

  • Qualified Person to AJ Vaccines

  • Chemist for Incoming Materials in QC department

  • QA/RA Manager

  • Supply Value Stream (SVS) Project Manager

  • Discovery Project Leader, Principal Scientist

  • Director, Head of Antibody Technology

See all jobs

Latest news

  • Novo Nordisk suffers Wegovy defeat to Viatris in patent court –
  • Pharmaceutical industry to grow 4% annually towards 2030 –
  • Zealand Pharma CEO: "We've never been stronger" –
  • Eli Lilly's head of diabetes and obesity retires –
  • DNB expects ALK's tablet sales to recover in 2024 –
  • Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees –
  • Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom –
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
See all

Jobs

  • Audit & Supplier Manager

  • VP of Software Development, Perfusion Tech

  • Senior Analytical Scientists

  • Senior Legal Councel

  • Senior QA Specialists (GMP or GCP)

  • Project Director, HR & ESG

  • Clinical Trial Manager

  • Scientist - Bioanalysis, Biologics

  • Clinical Supply Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Global Medical Manager

  • Qualified Person to AJ Vaccines

  • Chemist for Incoming Materials in QC department

  • QA/RA Manager

  • Supply Value Stream (SVS) Project Manager

  • Discovery Project Leader, Principal Scientist

  • Director, Head of Antibody Technology

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved